CATX Stock Summary and Trading Ideas (Perspective Therapeutics | AMEX:CATX)

Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.

Perspective Therapeutics trades on the AMEX stock market under the symbol CATX.

As of January 13, 2025, CATX stock price declined to $3.40 with 1,217,324 million shares trading.

CATX has a beta of 0.99, meaning it tends to be less sensitive to market movements. CATX has a correlation of 0.01 to the broad based SPY ETF.

CATX has a market cap of $229.80 million. This is considered a Small Cap stock.

Last quarter Perspective Therapeutics reported $369,000 in Revenue and -$.21 earnings per share. This beat revenue expectation by $199,000 and met earnings estimates .

The top ETF exchange traded funds that CATX belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.

CATX has underperformed the market in the last year with a return of -43.8%, while the SPY ETF gained +23.5%. In the last 3 month period, CATX fell short of the market, returning -74.3%, while SPY returned +1.3%. However, in the most recent 2 weeks CATX has outperformed the stock market by returning +6.6%, while SPY returned -2.3%.

CATX support price is $3.31 and resistance is $3.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CATX shares will trade within this expected range on the day.